Publisher's Synopsis
This volume discusses the preclinical and clinical experience with the B72.3 monoclonal anti-body as a tumour targeting agent - emphasizing the results of studies utilizing site-specifically radiolabelled B72.3 (CYT-103-111In; OncoScint CR103).;Focusing on OncoStint's ability to determine the presence and extent of disease in colorectal or ovarian cancer patients, this book: reviews the generation of the B72.3 monoclonal antibody and its development from preclinical trials to the first approved cancer imaging technology; presents the results of clinical trials of radioiodinated and indium-111 labelled material for colorectal cancer patients and considers the contribution of this procedure to their care; describes the use of CYT-103-111In as a presurgical diagnostic agent in ovarian cancer patients and its impact on their surgical management; and offers examples of normal biodistribution, tumour localization, and the potential pitfalls in image interpretation.;The book is intended for radiologists, internists, oncologists, nuclear medicine physicians, gastroenterologists, obstetricians/gynaecologists, immunologists and surgeons.
